JO3192B1 - مركب بنزوثيازولون - Google Patents

مركب بنزوثيازولون

Info

Publication number
JO3192B1
JO3192B1 JOP/2012/0250A JOP20120250A JO3192B1 JO 3192 B1 JO3192 B1 JO 3192B1 JO P20120250 A JOP20120250 A JO P20120250A JO 3192 B1 JO3192 B1 JO 3192B1
Authority
JO
Jordan
Prior art keywords
compound
present
benzothiazolone compound
benzothiazolone
provides
Prior art date
Application number
JOP/2012/0250A
Other languages
English (en)
Inventor
Grandeury Arnaud
Riebesehl Bernd
Erb Bernhard
Ullrich Thomas
Cao Jun
Zhou Jianguang
Alec Fairhurst Robin
Wu Xiang
Lai Xinzhong
Hatakeyama Shinji
Lustenberger Philipp
Koziczak-Holbro Magdalena
Tufilli Nicola
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47010668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3192(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3192B1 publication Critical patent/JO3192B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Cosmetics (AREA)

Abstract

يوفر الاختراع الحالي مركب بالصيغة (I) في الصورة الحرة أو في صورة ملح مقبول صيدليا (I) طريقة لتصنيع مركب الاختراع و استخداماته العلاجية. و يتعلق الاختراع الحالي اضافيا باتحاد من عوامل نشطة علاجيا و تركيبات صيدلية.
JOP/2012/0250A 2011-09-06 2012-09-04 مركب بنزوثيازولون JO3192B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011079379 2011-09-06

Publications (1)

Publication Number Publication Date
JO3192B1 true JO3192B1 (ar) 2018-03-08

Family

ID=47010668

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0250A JO3192B1 (ar) 2011-09-06 2012-09-04 مركب بنزوثيازولون

Country Status (39)

Country Link
US (6) US8933108B2 (ar)
EP (1) EP2753609B1 (ar)
JP (2) JP6130835B2 (ar)
KR (2) KR101800140B1 (ar)
CN (2) CN103781771B (ar)
AP (1) AP3830A (ar)
AR (1) AR087787A1 (ar)
AU (1) AU2013200422C1 (ar)
BR (1) BR112014004732A2 (ar)
CA (1) CA2845766A1 (ar)
CL (1) CL2014000493A1 (ar)
CO (1) CO6900147A2 (ar)
CR (1) CR20140114A (ar)
CU (1) CU24303B1 (ar)
CY (1) CY1118585T1 (ar)
DK (1) DK2753609T3 (ar)
EA (1) EA022909B1 (ar)
ES (1) ES2615052T3 (ar)
GT (1) GT201400042A (ar)
HR (1) HRP20170075T1 (ar)
HU (1) HUE030530T2 (ar)
IL (1) IL231235A (ar)
JO (1) JO3192B1 (ar)
LT (1) LT2753609T (ar)
MX (1) MX345405B (ar)
MY (1) MY163301A (ar)
PE (1) PE20141993A1 (ar)
PH (1) PH12014500399A1 (ar)
PL (1) PL2753609T3 (ar)
PT (1) PT2753609T (ar)
RS (1) RS55468B1 (ar)
SG (1) SG2014013114A (ar)
SI (1) SI2753609T1 (ar)
TN (1) TN2014000060A1 (ar)
TW (1) TWI555738B (ar)
UA (1) UA114295C2 (ar)
UY (1) UY34312A (ar)
WO (1) WO2013035047A1 (ar)
ZA (2) ZA201401112B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EP3243817A1 (en) * 2012-08-30 2017-11-15 Novartis AG Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
JP6230626B2 (ja) * 2013-02-28 2017-11-15 ノバルティス アーゲー ベンゾチアゾロン化合物を含む製剤
US10967119B1 (en) 2019-04-01 2021-04-06 Azizi Bilal Wearable medication injecting device

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149089T1 (de) * 1987-09-15 1997-03-15 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen agonisten
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1999009018A1 (en) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
CN1177831C (zh) 1998-12-04 2004-12-01 神经研究公司 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2004085058A1 (en) * 2003-03-26 2004-10-07 Pharmacia & Upjohn Company Llc Process to produce enantiomerically enriched alcohols and amines
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
JP2007503472A (ja) * 2003-06-10 2007-02-22 カリプシス・インコーポレーテッド 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物
EP1635800A2 (en) 2003-06-10 2006-03-22 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
JP2009513531A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
WO2005004852A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
GB0402797D0 (en) * 2004-02-09 2004-03-10 Novartis Ag Organic compounds
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
JP2007537187A (ja) 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
NZ570625A (en) 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
AU2007286051B2 (en) * 2006-08-10 2013-01-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) 2008-12-18 2009-01-28 Astrazeneca Ab New combination
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EP3243817A1 (en) * 2012-08-30 2017-11-15 Novartis AG Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
JP6230626B2 (ja) 2013-02-28 2017-11-15 ノバルティス アーゲー ベンゾチアゾロン化合物を含む製剤

Also Published As

Publication number Publication date
KR101628585B1 (ko) 2016-06-08
CU20140028A7 (es) 2014-05-27
CN103781771B (zh) 2016-08-24
HRP20170075T1 (hr) 2017-03-24
US20160279107A1 (en) 2016-09-29
SI2753609T1 (sl) 2017-03-31
BR112014004732A2 (pt) 2017-03-28
JP2014525472A (ja) 2014-09-29
IL231235A (en) 2017-09-28
DK2753609T3 (en) 2017-02-06
CO6900147A2 (es) 2014-03-20
US20180140582A1 (en) 2018-05-24
KR20160038079A (ko) 2016-04-06
RS55468B1 (sr) 2017-04-28
CR20140114A (es) 2014-05-06
EP2753609A1 (en) 2014-07-16
CA2845766A1 (en) 2013-03-14
US9913828B2 (en) 2018-03-13
US20160075670A1 (en) 2016-03-17
UA114295C2 (uk) 2017-05-25
WO2013035047A1 (en) 2013-03-14
JP2017132781A (ja) 2017-08-03
CL2014000493A1 (es) 2014-10-03
JP6130835B2 (ja) 2017-05-17
PE20141993A1 (es) 2014-12-17
JP6340103B2 (ja) 2018-06-06
US10251868B2 (en) 2019-04-09
CU24303B1 (es) 2018-01-10
GT201400042A (es) 2015-02-19
KR101800140B1 (ko) 2017-11-21
UY34312A (es) 2013-04-30
AR087787A1 (es) 2014-04-16
EA201490573A1 (ru) 2014-06-30
US20130245080A1 (en) 2013-09-19
MX2014002688A (es) 2014-04-14
CN106187942A (zh) 2016-12-07
ZA201401112B (en) 2016-01-27
CN106187942B (zh) 2020-06-26
AP3830A (en) 2016-09-30
ES2615052T3 (es) 2017-06-05
AU2013200422A1 (en) 2013-03-21
KR20140057382A (ko) 2014-05-12
TW201317221A (zh) 2013-05-01
PH12014500399A1 (en) 2021-06-02
US20150094346A1 (en) 2015-04-02
IL231235A0 (en) 2014-04-30
NZ621089A (en) 2015-07-31
LT2753609T (lt) 2017-01-10
TN2014000060A1 (en) 2015-07-01
ZA201500790B (en) 2017-04-26
SG2014013114A (en) 2014-07-30
AU2013200422B2 (en) 2014-08-07
EP2753609B1 (en) 2016-11-09
MX345405B (es) 2017-01-30
PL2753609T3 (pl) 2017-05-31
TWI555738B (zh) 2016-11-01
HUE030530T2 (en) 2017-05-29
CN103781771A (zh) 2014-05-07
AP2014007462A0 (en) 2014-02-28
US8933108B2 (en) 2015-01-13
AU2013200422C1 (en) 2015-01-15
CY1118585T1 (el) 2017-07-12
PT2753609T (pt) 2017-02-08
MY163301A (en) 2017-09-15
EA022909B1 (ru) 2016-03-31
US20150336914A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
IN2015DN00185A (ar)
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX375731B (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
CY1118585T1 (el) Ενωση βενζοθειαζολονης
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist